Biogen Analysts Boost Their Forecasts After Upbeat Q4 Earnings

Benzinga

Feb 09

Biogen Inc. (NASDAQ:BIIB) on Friday reported better-than-expected fourth-quarter earnings.

The company posted quarterly adjusted EPS of $1.99, beating the consensus of $1.59. The Alzheimer’s drug maker reported revenues of $2.28 billion, beating the consensus of $2.20 billion, down 7% on a reported and constant currency basis.

“Our 2025 performance reflected continued focus on strong execution and financial discipline, driven by our revenue of nearly $1 billion from LEQEMBI, SKYCLARYS, ZURZUVAE, and QALSODY, progression of our pipeline, and resilience of our MS franchise,” commented Christopher Viehbacher, President and CEO.

Biogen expects fiscal 2026 earnings between $15.25 and $16.25 per share, versus the consensus of $14.92. The company expects revenue to decline by mid-single digits compared to 2025, as further declines in Multiple sclerosis product revenue, excluding Vumerity, are expected to be partially offset by increases in revenue from growth

Biogen shares fell 0.9% to $199.40 in pre-market trading.

These analysts made changes to their price targets on Biogen following earnings announcement.

Piper Sandler analyst David Amsellem maintained Biogen with a Neutral and raised the price target from $157 to $177.
HC Wainwright & Co. analyst Andrew S. Fein maintained the stock with a Buy and raised the price target from $194 to $228.
Wedbush analyst Laura Chico maintained Biogen with a Neutral and boosted the price target from $178 to $187.

Considering buying BIIB stock? Here’s what analysts think:

Photo via Shutterstock

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610558636"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610558636\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610558636?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-09 21:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610558636","market":"us","top_or_hot":-1,"title":"Biogen Analysts Boost Their Forecasts After Upbeat Q4 Earnings","media":"Benzinga","content":"<html><body><p><strong>Biogen Inc.</strong> (NASDAQ:BIIB) on Friday reported better-than-expected fourth-quarter earnings.</p>\n<p>The company posted quarterly adjusted EPS of $1.99, beating the consensus of $1.59. The Alzheimer’s drug maker reported revenues of $2.28 billion, beating the consensus of $2.20 billion, down 7% on a reported and constant currency basis.</p>\n<p>“Our 2025 performance reflected continued focus on strong execution and financial discipline, driven by our revenue of nearly $1 billion from LEQEMBI, SKYCLARYS, ZURZUVAE, and QALSODY, progression of our pipeline, and resilience of our MS franchise,” commented Christopher Viehbacher, President and CEO.</p>\n<p>Biogen expects fiscal 2026 earnings between $15.25 and $16.25 per share, versus the consensus of $14.92. The company expects revenue to decline by mid-single digits compared to 2025, as further declines in Multiple sclerosis product revenue, excluding Vumerity, are expected to be partially offset by increases in revenue from growth</p>\n<p>Biogen shares fell 0.9% to $199.40 in pre-market trading.</p>\n<p>These analysts made changes to their price targets on Biogen following earnings announcement.</p>\n<ul>\n<li>Piper Sandler analyst David Amsellem maintained Biogen with a Neutral and raised the price target from $157 to $177.</li>\n<li>HC Wainwright &amp; Co. analyst Andrew S. Fein maintained the stock with a Buy and raised the price target from $194 to $228.</li>\n<li>Wedbush analyst Laura Chico maintained Biogen with a Neutral and boosted the price target from $178 to $187.</li>\n</ul>\n<p><strong>Considering buying BIIB stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"511\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/09083458/image-171-1024x511.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/09083458/image-171-1024x511.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/09083458/image-171-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/09083458/image-171-768x383.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/09083458/image-171.png 1197w\" width=\"1024\"/></figure>\n<p>Photo via Shutterstock</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen Analysts Boost Their Forecasts After Upbeat Q4 Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen Analysts Boost Their Forecasts After Upbeat Q4 Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2026-02-09 21:36</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong>Biogen Inc.</strong> (NASDAQ:BIIB) on Friday reported better-than-expected fourth-quarter earnings.</p>\n<p>The company posted quarterly adjusted EPS of $1.99, beating the consensus of $1.59. The Alzheimer’s drug maker reported revenues of $2.28 billion, beating the consensus of $2.20 billion, down 7% on a reported and constant currency basis.</p>\n<p>“Our 2025 performance reflected continued focus on strong execution and financial discipline, driven by our revenue of nearly $1 billion from LEQEMBI, SKYCLARYS, ZURZUVAE, and QALSODY, progression of our pipeline, and resilience of our MS franchise,” commented Christopher Viehbacher, President and CEO.</p>\n<p>Biogen expects fiscal 2026 earnings between $15.25 and $16.25 per share, versus the consensus of $14.92. The company expects revenue to decline by mid-single digits compared to 2025, as further declines in Multiple sclerosis product revenue, excluding Vumerity, are expected to be partially offset by increases in revenue from growth</p>\n<p>Biogen shares fell 0.9% to $199.40 in pre-market trading.</p>\n<p>These analysts made changes to their price targets on Biogen following earnings announcement.</p>\n<ul>\n<li>Piper Sandler analyst David Amsellem maintained Biogen with a Neutral and raised the price target from $157 to $177.</li>\n<li>HC Wainwright &amp; Co. analyst Andrew S. Fein maintained the stock with a Buy and raised the price target from $194 to $228.</li>\n<li>Wedbush analyst Laura Chico maintained Biogen with a Neutral and boosted the price target from $178 to $187.</li>\n</ul>\n<p><strong>Considering buying BIIB stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"511\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/09083458/image-171-1024x511.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/09083458/image-171-1024x511.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/09083458/image-171-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/09083458/image-171-768x383.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/09083458/image-171.png 1197w\" width=\"1024\"/></figure>\n<p>Photo via Shutterstock</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BIIB","symbol_name":"渤健公司","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/02/50477635/biogen-analysts-boost-their-forecasts-after-upbeat-q4-earnings","article_id":"2610558636","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610558636","pubTimestamp":1770644161,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":" ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BIIB":"渤健公司"},"translate_title":"百健(Biogen)分析师在第四季度盈利乐观后上调预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":1.5},"content_text":"Biogen Inc. (NASDAQ:BIIB) on Friday reported better-than-expected fourth-quarter earnings.\nThe company posted quarterly adjusted EPS of $1.99, beating the consensus of $1.59. The Alzheimer’s drug maker reported revenues of $2.28 billion, beating the consensus of $2.20 billion, down 7% on a reported and constant currency basis.\n“Our 2025 performance reflected continued focus on strong execution and financial discipline, driven by our revenue of nearly $1 billion from LEQEMBI, SKYCLARYS, ZURZUVAE, and QALSODY, progression of our pipeline, and resilience of our MS franchise,” commented Christopher Viehbacher, President and CEO.\nBiogen expects fiscal 2026 earnings between $15.25 and $16.25 per share, versus the consensus of $14.92. The company expects revenue to decline by mid-single digits compared to 2025, as further declines in Multiple sclerosis product revenue, excluding Vumerity, are expected to be partially offset by increases in revenue from growth\nBiogen shares fell 0.9% to $199.40 in pre-market trading.\nThese analysts made changes to their price targets on Biogen following earnings announcement.\n\nPiper Sandler analyst David Amsellem maintained Biogen with a Neutral and raised the price target from $157 to $177.\nHC Wainwright & Co. analyst Andrew S. Fein maintained the stock with a Buy and raised the price target from $194 to $228.\nWedbush analyst Laura Chico maintained Biogen with a Neutral and boosted the price target from $178 to $187.\n\nConsidering buying BIIB stock? Here’s what analysts think: \n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}